Corporate News

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, confirms that it will be announcing its half year results for the six months ended 30 June 2023 on Thursday, 7 September 2023.

Christopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation relating to the results via the Investor Meet Company platform on Friday, 15 September 2023 at 10am BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your IMC dashboard up until 9am the day before the meeting or in real time during the presentation.

Investors can sign up to Investor Meet Company for free and add to meet Polarean Imaging Plc here. Investors who already follow Polarean on the Investor Meet Company platform will automatically be invited.

Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.

Enquiries: 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean’s vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States.   The company also commercialises systems (such as the HPX hyperpolarisation system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.

PLC-RNS-2318